EMA Authorised: Fasenra (Benralizumab) — AstraZeneca AB

View source ↗

Summary

EMA authorised Fasenra (benralizumab) for asthma. The marketing authorisation holder is AstraZeneca AB; decision date 13/02/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

Status: Authorised. Therapeutic area: Asthma. MAH: AstraZeneca AB. Decision date: 13/02/2025